Co-occurring mutations in the POLE exonuclease and non-exonuclease domains define a unique subset of highly mutagenic tumors
暂无分享,去创建一个
R. Dunbrack | J. Swensen | M. Hall | L. Valle | P. Mur | J. Xiu | S. Shah | S. Arora | E. Demidova | Mark Andrake | Bulat Faezov | Salena Ringenbach | Julen Viana-Errasti | S. Shah
[1] C. Tournigand,et al. PD-1 blockade in solid tumors with defects in polymerase epsilon. , 2022, Cancer discovery.
[2] J. Shen,et al. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers , 2022, JCO precision oncology.
[3] Scott R. Kennedy,et al. Probing the mechanisms of two exonuclease domain mutators of DNA polymerase ϵ. , 2022, Nucleic acids research.
[4] Trevor J Pugh,et al. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency , 2022, Nature medicine.
[5] M. Stratton,et al. Increased somatic mutation burdens in normal human cells due to defective DNA polymerases , 2021, Nature Genetics.
[6] K. Kavukcuoglu,et al. Highly accurate protein structure prediction for the human proteome , 2021, Nature.
[7] Oriol Vinyals,et al. Highly accurate protein structure prediction with AlphaFold , 2021, Nature.
[8] G. Getz,et al. DNA polymerase and mismatch repair exert distinct microsatellite instability signatures in normal and malignant human cells. , 2020, Cancer discovery.
[9] H. Okkels,et al. New Pathogenic Germline Variants in Very Early Onset and Familial Colorectal Cancer Patients , 2020, Frontiers in Genetics.
[10] T. Pons,et al. Role of POLE and POLD1 in familial cancer , 2020, Genetics in Medicine.
[11] R. Georgescu,et al. Structure of the polymerase ε holoenzyme and atomic model of the leading strand replisome , 2020, Nature Communications.
[12] Z. Pursell,et al. POLE Mutation Spectra Are Shaped by the Mutant Allele Identity, Its Abundance, and Mismatch Repair Status. , 2020, Molecular cell.
[13] A. Spurdle,et al. Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants , 2020, medRxiv.
[14] A. Stenzinger,et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project , 2020, Journal for ImmunoTherapy of Cancer.
[15] C. Gilks,et al. Interpretation of somatic POLE mutations in endometrial carcinoma , 2019, The Journal of pathology.
[16] Z. Pursell,et al. POLE proofreading defects: Contributions to mutagenesis and cancer. , 2019, DNA repair.
[17] M. Ebsen,et al. POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma , 2019, Oncotarget.
[18] Liping He,et al. DeepDDG: Predicting the Stability Change of Protein Point Mutations Using Neural Networks , 2019, J. Chem. Inf. Model..
[19] Sushma Sharma,et al. A recurrent cancer-associated substitution in DNA polymerase ε produces a hyperactive enzyme , 2019, Nature Communications.
[20] S. C. Kamerlin,et al. Structural consequence of the most frequently recurring cancer-associated substitution in DNA polymerase ε , 2019, Nature Communications.
[21] C. Toulas,et al. Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma , 2018, Familial Cancer.
[22] C. Toulas,et al. Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma , 2018, Familial Cancer.
[23] H. Masuyama,et al. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability , 2018, PloS one.
[24] K. Cole,et al. Comprehensive Analysis of Hypermutation in Human Cancer , 2017, Cell.
[25] T. Tahirov,et al. Crystal structure of the human Polϵ B-subunit in complex with the C-terminal domain of the catalytic subunit , 2017, The Journal of Biological Chemistry.
[26] Roland L. Dunbrack,et al. The Rosetta all-atom energy function for macromolecular modeling and design , 2017, bioRxiv.
[27] Sung‐Min Ahn,et al. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy , 2016, Oncotarget.
[28] E. Golemis,et al. POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies , 2016, Gene.
[29] C. Lázaro,et al. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. , 2014, Human molecular genetics.
[30] E. Johansson,et al. Structural basis for processive DNA synthesis by yeast DNA polymerase ɛ , 2013, Nature Structural &Molecular Biology.
[31] Peter Donnelly,et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas , 2013, Nature Genetics.